In addition, plasma CXCL9 has been found to predict the survival of patients with advanced pancreatic ductal adenocarcinoma receiving chemotherapy, potentially improving treatment outcomes (Qian et al., 2019). This evidence concerns the gene CXCL9 and pancreatic ductal adenocarcinoma.